The IL2RA gene¹¹ IL2RA gene
IL2RA encodes CD25, the alpha chain of the interleukin-2 receptor, which forms the high-affinity IL-2 receptor complex together with the beta (CD122) and gamma (CD132) chains sits at a critical junction of immune self-tolerance. CD25 is the defining surface marker of regulatory T cells²² regulatory T cells
Tregs are a specialized CD4+ T cell population that suppress immune responses and prevent autoimmunity; CD25 is constitutively expressed at high levels on their surface, giving Tregs preferential access to IL-2 (Tregs), and IL-2 signaling through the high-affinity receptor complex is the master signal for Treg survival, proliferation, and suppressive function. rs12722489 lies within the first intron of IL2RA and controls how much of the receptor gets made — but through an unexpected mechanism involving the sex hormone estrogen.

The Mechanism

Unlike typical intronic variants that quietly affect splicing or have no known function, rs12722489 has been shown to create an allele-specific estrogen response element³³ allele-specific estrogen response element
An estrogen response element (ERE) is a short DNA sequence that binds estrogen receptor alpha, driving nearby gene transcription when estrogen is present. The risk C allele (reported as G in coding-strand notation, since IL2RA sits on the minus strand) forms a sequence that binds estrogen receptor alpha (ERα) with high affinity. The protective T allele does not.

Three independent laboratory methods confirmed this: electrophoretic mobility shift assay⁴⁴ electrophoretic mobility shift assay
EMSA detects protein-DNA binding by showing a band shift when a protein grabs a DNA fragment showed ERα binding to the C-allele sequence but not the T-allele sequence; chromatin immunoprecipitation confirmed endogenous ERα bound the rs12722489 region in live cells; and a luciferase reporter assay⁵⁵ luciferase reporter assay
Reporter assay: a gene with no cellular function (luciferase) is placed downstream of the test sequence; if the sequence drives transcription, luciferase lights up measurably demonstrated that a 1-kilobase intronic segment containing the C allele enhances promoter activity in a dose-dependent, estrogen-dependent fashion — while the T-allele version of the same segment has no enhancer activity.

The downstream consequence is elevated IL2RA transcription in response to estrogen. This connects two independently recognized phenomena: the strong female predominance of most autoimmune diseases (with estrogen as a key driver) and the role of IL2RA variants in predisposing to them. When estrogen levels are high — throughout most of a woman's reproductive years — the C allele amplifies IL2RA expression in a way the T allele does not. The precise immunological consequences are still being characterized, but excess IL2RA expression is associated with elevated soluble IL-2RA shedding⁶⁶ soluble IL-2RA shedding
Soluble IL-2RA (sIL-2RA) is shed from the cell surface into the blood, where it competes with membrane-bound receptors for IL-2, acting as a decoy that reduces effective Treg stimulation — the same mechanism established for the linked variant rs2104286.

The two variants at this locus, rs12722489 and rs2104286, are in moderate linkage disequilibrium⁷⁷ moderate linkage disequilibrium
r² = 0.62, meaning they are correlated but not identical; they partially tag each other but each captures some independent variation (r² = 0.62). Conditioning analysis in large MS datasets has found that the rs12722489 signal is largely explained by rs2104286, but the estrogen-receptor binding function provides a mechanistic explanation specific to this variant that may become more or less relevant depending on hormonal status.

The Evidence

The MS association was first identified in genome-wide association studies⁸⁸ genome-wide association studies
The International Multiple Sclerosis Genetics Consortium original GWAS reported the IL2RA locus at P = 2.96 × 10⁻⁸, with rs12722489 among the associated variants of the International Multiple Sclerosis Genetics Consortium and subsequently replicated in two independent European populations⁹⁹ replicated in two independent European populations
Weber et al. genotyped French and German case-control cohorts totaling over 2,000 individuals; OR range 1.1–1.5. A meta-analysis of six studies¹⁰¹⁰ meta-analysis of six studies
Wang et al. 2018, pooling 4,259 MS cases and 5,420 controls across populations totalling 4,259 MS cases and 5,420 controls established the C allele risk association in Caucasians at OR 1.20 (95% CI 1.12–1.29, p < 0.001), with no significant association in Asians (OR 1.10, 95% CI 0.75–1.63, p = 0.629).

A broader IL2RA heterogeneity study¹¹¹¹ IL2RA heterogeneity study
Maier et al. PLOS Genetics 2009, examining both MS and T1D cohorts examining both MS and type 1 diabetes confirmed the rs12722489 and rs2104286 variants in moderate LD and documented that risk haplotypes at this locus elevate serum soluble IL-2RA across both disease contexts — a biomarker of reduced effective Treg IL-2 signaling. The functional confirmation¹²¹² functional confirmation
Garg et al. 2012 in J. Immunology, demonstrating via the linked IL2RA locus variant rs12722495 that IL2RA haplotype-dependent reduction in STAT5 phosphorylation translates to impaired FoxP3 expression and suppressive function that IL2RA risk haplotypes reduce pSTAT5 signaling in Tregs and impair their suppressive capacity provides mechanistic grounding for why these intronic variants translate into immune dysregulation.

The estrogen receptor binding study¹³¹³ estrogen receptor binding study
Afanasyeva et al. PLoS One 2017, the definitive molecular characterization of this specific SNP identified rs12722489 as the specific molecular switch, explaining associations observed across rheumatoid arthritis, multiple sclerosis, Crohn's disease, and ulcerative colitis — all diseases that share female predominance and Treg dysfunction as core features.

Practical Implications

The C allele is the common allele in almost every population — roughly 85% of Europeans, 97% of Africans, and 87% of East Asians carry it. Being CC homozygous is the baseline in most populations. The TT genotype (fully protective) is rare (~2% of Europeans) and represents a genuinely unusual configuration.

For CC homozygotes, the risk is real but modest in absolute terms. MS affects roughly 0.1–0.3% of Europeans, and carrying two C alleles raises that approximately 1.4-fold to around 0.14–0.43% — still a low absolute risk. The same applies to type 1 diabetes and other autoimmune associations. What the genotype does establish is a background of moderately reduced Treg signaling efficiency, which can be partially offset by nutritional and lifestyle strategies that support IL-2-independent Treg maintenance pathways.

Vitamin D directly promotes Treg differentiation, significantly increasing the frequency of FoxP3+ regulatory T cells in healthy individuals¹⁴¹⁴ significantly increasing the frequency of FoxP3+ regulatory T cells in healthy individuals
Observational trial: vitamin D supplementation raised %Tregs from 4.8% to 5.9% over four weeks (P < 0.001) — a parallel route to Treg maintenance that bypasses the compromised IL-2/CD25 signaling axis. Omega-3 fatty acids (EPA and DHA) offer another Treg-supporting pathway through PPAR-gamma activation.

Interactions

rs12722489 and rs2104286 are two partially independent signals within the same IL2RA intron 1 region. Their r² of 0.62 means they are correlated but not redundant — a subset of individuals will carry the rs12722489 risk allele without the rs2104286 risk allele and vice versa. Fine-mapping studies suggest rs2104286 carries more of the statistical MS signal in large combined analyses, but the estrogen-receptor binding function of rs12722489 may confer distinct effects in females during periods of high estrogen exposure (reproductive years, exogenous estrogen use).

The combination with CTLA4 rs3087243 is worth noting. CTLA4 encodes a key co-inhibitory receptor on Tregs; IL2RA rs12722489 impairs IL-2 signaling to Tregs while CTLA4 rs3087243 reduces their co-inhibitory capacity. These represent parallel, independent routes to Treg dysfunction that may compound the risk for autoimmune disease in carriers of both risk alleles.

Every milligram of zinc you absorb from food must cross two membranes in your intestinal cells. ZIP4 ferries zinc in from the gut lumen at the cell's apical face; ZnT1 (SLC30A1)¹¹ ZnT1 (SLC30A1)
Solute Carrier Family 30 Member 1 — the primary zinc efflux transporter at the basolateral membrane of enterocytes, releasing absorbed zinc into the portal circulation then pumps it out the other side into the bloodstream. Without functional ZnT1, zinc is absorbed but trapped in the intestinal cell wall — it cannot reach the liver, immune cells, or any other tissue that depends on it. rs12734494 lies approximately 51 kb downstream of the SLC30A1 gene in an intergenic region on chromosome 1q32.3, a position consistent with a regulatory element that modulates ZnT1 expression levels.

The Mechanism

The rs12734494 A allele shows a striking population frequency pattern: it is common in European (~49%), African (~43%), and South Asian (~45%) populations, but rare in East Asian populations (~8%). This degree of population differentiation — far greater than expected for a neutral intergenic variant — points to selective pressure on the SLC30A1 regulatory landscape, possibly tied to historical differences in dietary zinc availability across populations.

SLC30A1 expression is itself dynamically regulated by zinc status. When intracellular zinc rises, the transcription factor MTF-1 binds metal response elements in the SLC30A1 promoter and increases ZnT1 expression, accelerating zinc export. When zinc is scarce, SLC30A1 mRNA and protein fall to conserve zinc within the cell. Cragg et al. 2005²² Cragg et al. 2005
Cragg RA et al. Homeostatic regulation of zinc transporters in the human small intestine by dietary zinc supplementation. Gut. 2005 demonstrated this directly in a double-blind, placebo-controlled crossover trial: 25 mg/day zinc supplementation for 14 days reduced intestinal SLC30A1 mRNA 1.4-fold and protein 3.7-fold in human ileostomy patients. An intergenic variant at rs12734494 could modulate the sensitivity or baseline tone of this regulatory response, influencing how efficiently absorbed zinc is exported into circulation.

The functional consequence of the specific A allele at this locus has not yet been characterized in isolation at the molecular level. The evidence here is based on population genetics (selective pressure signal) and the well-characterized biology of ZnT1 in zinc homeostasis — not direct functional studies of this variant. This is an emerging-evidence SNP.

The Evidence

ZnT1 is essential for systemic zinc supply. Sun et al. 2024³³ Sun et al. 2024
Sun S et al. The Intestinal Transporter SLC30A1 Plays a Critical Role in Regulating Systemic Zinc Homeostasis. Adv Sci. 2024 showed that inducible knockout of intestinal Slc30a1 in adult mice caused lethal zinc deficiency within two weeks — a phenotype completely rescued by intraperitoneal zinc supplementation. The cryo-EM structure identified His43 as the critical zinc-selectivity residue, and cryo-EM confirmed localization to the basolateral enterocyte membrane.

ZnT1 affects immune function. Na-Phatthalung et al. 2024⁴⁴ Na-Phatthalung et al. 2024
Na-Phatthalung P et al. The zinc transporter Slc30a1 (ZnT1) in macrophages plays a protective role against attenuated Salmonella. eLife. 2024 demonstrated that ZnT1-deficient macrophages have impaired NF-κB activation and reduced nitric oxide production, leading to defective intracellular killing of Salmonella. This connects ZnT1 function directly to innate immunity.

Population-level selective pressure. Roca-Umbert et al. 2022⁵⁵ Roca-Umbert et al. 2022
Roca-Umbert A et al. Understanding signatures of positive natural selection in human zinc transporter genes. Sci Rep. 2022 confirmed that zinc transporter genes as a group show higher genetic differentiation between African and non-African populations than expected by chance, with signals of positive selection linked to regional zinc availability in soil and diet.

The marked depletion of the A allele in East Asian populations (7.6% vs. 43–49% elsewhere) is consistent with selective maintenance of the G allele in populations historically consuming diets lower in bioavailable zinc (plant-heavy, high-phytate diets), where efficient zinc export — potentially requiring the ancestral G configuration — may have been advantageous for fine-tuned homeostatic regulation.

Practical Implications

For carriers of the AA genotype, monitoring serum zinc status is more informative than relying on dietary estimates alone. Zinc bioavailability varies considerably by food matrix, and a variant near the primary basolateral exporter could affect how efficiently absorbed zinc reaches the bloodstream. Zinc-rich whole foods with high bioavailability (shellfish, red meat) and avoiding high-phytate meals paired with zinc sources are relevant strategies given uncertain zinc transport efficiency at this locus.

Interactions

The companion zinc GWAS SNP rs2120019 (PPCDC, chromosome 15) is a validated genetic instrument for serum zinc levels, lowering zinc by approximately 0.3 standard deviations per C allele. Carriers of the rs12734494 A allele who also carry the rs2120019 C allele may face additive impairment of zinc status from two independent mechanisms — reduced transporter efficiency at the intestinal basolateral membrane (SLC30A1) and altered metabolite-mediated zinc regulation (PPCDC pathway). No published compound interaction study exists yet, but the pathway logic is direct.

Your chromosomes contain regulatory switches that control how much cholesterol circulates in your blood. At position 1p13.3 on chromosome 1, a single-letter DNA change creates or destroys a binding site for a protein called C/EBP¹¹ C/EBP
CCAAT/enhancer binding protein, a transcription factor that regulates gene expression, fundamentally altering your liver's cholesterol management system.

This variant, rs12740374, sits in the 3' untranslated region of the CELSR2 gene but controls expression of SORT1, which encodes sortilin²² sortilin
a cellular trafficking receptor that directs proteins to different destinations within cells. When the T allele is present, it creates a functional C/EBP binding site that increases sortilin production in liver cells by more than 12-fold³³ more than 12-fold
compared to the major G allele. This isn't a subtle effect — it's one of the strongest genetic regulators of LDL cholesterol discovered through genome-wide studies.

The Mechanism

Sortilin acts as an intracellular sorting receptor in hepatocytes, binding to apolipoprotein B-100 (apoB) in the Golgi apparatus. When sortilin levels are high (T allele carriers), it captures apoB-containing particles and routes them to lysosomes for degradation⁴⁴ captures apoB-containing particles and routes them to lysosomes for degradation
rather than allowing them to be secreted as VLDL particles, reducing the amount of VLDL that leaves the liver. Since VLDL particles are converted to LDL in circulation, less VLDL secretion means lower plasma LDL cholesterol.

The molecular switch works like this: the T allele creates a perfect C/EBP consensus binding site, while the G allele disrupts it. When C/EBP binds to the T allele sequence, it increases SORT1 transcription. Reporter assays show ~4-fold greater gene activity⁵⁵ ~4-fold greater gene activity
with the T allele compared to G in laboratory experiments.

Importantly, sortilin's effect is context-dependent. It restricts apoB secretion specifically under conditions of lipid loading and endoplasmic reticulum stress⁶⁶ lipid loading and endoplasmic reticulum stress
metabolic conditions common after high-fat meals, but has minimal effect under basal conditions. This suggests the variant may be particularly important during metabolic challenges.

Beyond reducing VLDL secretion, increased hepatic sortilin also enhances LDL catabolism⁷⁷ enhances LDL catabolism
the breakdown and clearance of LDL particles from the blood, working through two complementary mechanisms to lower circulating LDL cholesterol.

The Evidence

The 1p13.3 locus ranks among the most robustly replicated genetic associations in cardiovascular disease. Genome-wide association studies⁸⁸ Genome-wide association studies
meta-analyses combining hundreds of thousands of individuals consistently identify rs12740374 and its tightly linked neighbors (rs646776, rs599839) as major LDL-cholesterol regulators.

Effect sizes are clinically meaningful. Each copy of the T allele (the higher-sortilin, protective allele) lowers LDL cholesterol by approximately 0.18-0.19 mmol/L (7-7.5 mg/dL)⁹⁹ 0.18-0.19 mmol/L (7-7.5 mg/dL)
observed in both European Americans and African Americans in the ARIC Study. Other studies report reductions of 5-11 mg/dL per T allele¹⁰¹⁰ 5-11 mg/dL per T allele
effect size varies by ancestry, with Mexican Americans showing ~11 mg/dL reduction.

The cardiovascular benefit is substantial. Homozygosity for the protective T allele is associated with a 40% reduction in myocardial infarction risk¹¹¹¹ 40% reduction in myocardial infarction risk
compared to GG homozygotes, with odds ratios in the 0.51 range for coronary stenosis. The effect is mediated primarily through LDL-cholesterol lowering, though the variant also reduces protein C levels¹²¹² reduces protein C levels
a coagulation factor, suggesting a novel link between lipoprotein metabolism and hemostasis.

Effect sizes are considerably larger in younger populations¹³¹³ considerably larger in younger populations
2.5-4.1% of LDL-C variation in children and young adults, versus 1% in older subjects, suggesting early-life effects may be particularly important for lifelong cardiovascular risk.

Functional studies in mice confirm the mechanism. Sort1 knockout mice show reduced lipoprotein secretion and protection from hypercholesterolemia¹⁴¹⁴ reduced lipoprotein secretion and protection from hypercholesterolemia
when crossed with LDL receptor-deficient mice, while sortilin overexpression increases plasma LDL levels. RNA interference studies in human hepatocytes demonstrate that silencing SORT1 reduces apoB secretion.

A pharmacogenetic meta-analysis¹⁵¹⁵ pharmacogenetic meta-analysis
of statin response studies found that rs12740374 is associated with an additional 1.5% increase per T allele in LDL-C lowering when treated with statins, suggesting the variant may predict drug response.

Practical Actions

If you carry one or two copies of the protective T allele, you start with a genetic advantage for cholesterol management. Your liver naturally produces more sortilin, routing more apoB to degradation and secreting less VLDL. This doesn't mean you're immune to high cholesterol — diet, exercise, and other genetic factors still matter — but you have a lower baseline risk.

For GG homozygotes, the opposite applies: less sortilin means more efficient VLDL secretion and higher baseline LDL-cholesterol. This genetic predisposition makes lifestyle modifications particularly important¹⁶¹⁶ lifestyle modifications particularly important
dietary interventions that reduce LDL-C are especially valuable when genetic factors work against you.

Dietary fiber and plant sterols work through complementary mechanisms. Soluble fiber¹⁷¹⁷ Soluble fiber
5-10 grams daily from oats, barley, psyllium, beans, and vegetables reduces intestinal cholesterol absorption. Plant sterols/stanols¹⁸¹⁸ Plant sterols/stanols
2 grams daily from fortified foods or supplements compete with cholesterol for absorption, lowering LDL-C by 5-15%. A dietary portfolio combining these approaches can reduce LDL-C by ~30%, rivaling first-line statin therapy.

Since sortilin's effects are amplified under conditions of lipid loading and ER stress¹⁹¹⁹ conditions of lipid loading and ER stress
high-fat meals and metabolic stress, GG carriers may see particular benefit from moderating saturated fat intake. Studies show saturated fatty acids activate ERK signaling and suppress Sort1 expression²⁰²⁰ activate ERK signaling and suppress Sort1 expression
in obese and diabetic mice, potentially worsening the GG genotype's baseline disadvantage.

Interactions

The 1p13.3 locus is part of a broader polygenic architecture of LDL cholesterol. Variants in APOE, LDLR, PCSK9, APOB, and HMGCR²¹²¹ APOE, LDLR, PCSK9, APOB, and HMGCR
other major cholesterol-regulating genes combine additively to determine overall cholesterol levels and cardiovascular risk. Genetic risk scores incorporating these loci predict familial hypercholesterolemia in patients without monogenic mutations.

The nearby variants rs646776 and rs599839 are in near-perfect linkage disequilibrium with rs12740374²²²² near-perfect linkage disequilibrium with rs12740374
r² > 0.98, meaning they're almost always inherited together and represent the same biological signal. Other SNPs in this haplotype block include rs629301, rs1277930, and rs583104.

Gene-diet interactions have been observed. While the locus primarily affects baseline LDL-cholesterol, dietary interventions still work: carriers of the higher-risk G allele respond normally to soluble fiber, plant sterols, and Mediterranean dietary patterns²³²³ respond normally to soluble fiber, plant sterols, and Mediterranean dietary patterns
these interventions lower LDL-C regardless of genotype.

Statin pharmacogenetics show that rs12740374 predicts treatment response, with T allele carriers achieving slightly greater LDL-C reduction²⁴²⁴ slightly greater LDL-C reduction
an additional 1.5% per allele on statin therapy. This suggests that genetic testing could help predict who will achieve guideline LDL-C targets on first-line therapy versus requiring combination treatment.

Gene-Gene Interaction Proposals

SORT1 × APOE (rs12740374 × rs429358/rs7412): APOE genotype determines LDL receptor affinity, while SORT1 controls hepatic VLDL secretion. The combination of SORT1 GG (high VLDL secretion) with APOE ε4/ε4 (impaired LDL clearance) may create a compound risk state requiring aggressive dietary or pharmacologic intervention. Conversely, SORT1 TT × APOE ε2/ε2 might confer exceptional protection. Evidence: both loci are included in polygenic risk scores for hypercholesterolemia²⁵²⁵ polygenic risk scores for hypercholesterolemia
and show additive effects.

SORT1 × PCSK9 (rs12740374 × rs11591147): PCSK9 degrades LDL receptors, while sortilin controls VLDL production and facilitates PCSK9 secretion²⁶²⁶ facilitates PCSK9 secretion
SORT1 enhances PCSK9 secretion from hepatocytes. SORT1 GG (low sortilin) with PCSK9 gain-of-function variants may compound LDL-C elevation through both increased production and reduced clearance. Evidence: PCSK9 and LDLR show documented interaction effects²⁷²⁷ PCSK9 and LDLR show documented interaction effects
on statin response.

TRAF3IP2 encodes Act1 (also called CIKS — Connector of IKK and Stress-activated kinases), the essential adaptor protein for IL-17 receptor signaling¹¹ the essential adaptor protein for IL-17 receptor signaling
Act1 bridges the cytoplasmic domain of IL-17RA/IL-17RC to TRAF6, activating NF-κB and inflammatory gene expression in keratinocytes, fibroblasts, and mucosal epithelial cells; it is also a negative regulator of B-cell adaptive immunity via its interaction with the CD40 signaling complex. While the most studied variants at this locus — D10N (rs33980500) and R74W (rs13190932) — affect the Act1 protein directly, rs13193677 was identified in the same three-SNP panel as part of a 2013 Italian cohort study that extended TRAF3IP2 disease associations beyond psoriasis and psoriatic arthritis into systemic lupus erythematosus (SLE) territory.

The Variant

rs13193677 sits at chr6:154,297,800 (GRCh38). Current dbSNP annotation places it within the IPCEF1 gene (interaction protein for cytohesin exchange factors 1) at chromosome 6q25.2 — approximately 43 megabases distal to the canonical TRAF3IP2 locus at 6q21. This chromosomal distance means rs13193677 cannot be in significant linkage disequilibrium with the TRAF3IP2 coding variants (rs33980500, rs13190932) by standard LD block structure.

The Ciccacci 2013 investigators selected rs13193677 as part of their TRAF3IP2 panel based on earlier TRAF3IP2 literature and genotyping array content, but the variant's independent association with SLE susceptibility (OR=1.73, P=0.046) and pericarditis in that cohort likely reflects an action at the IPCEF1/6q25.2 locus itself rather than a TRAF3IP2 LD-tagging effect. IPCEF1 encodes a protein that regulates ARF6 GEF activity through cytohesin-2, participates in membrane trafficking, and shows nerve injury-responsive expression — a functional context distinct from Act1/IL-17 signaling.

On the plus strand (as reported by dbSNP), the reference allele is G and the alternate allele is A. The A allele is rare in East Asian populations (~0.1%) but reaches ~9% in Europeans and ~13% in Africans, consistent with the population distribution of many autoimmune risk alleles.

The Evidence

The primary evidence comes from Ciccacci et al. 2013²² Ciccacci et al. 2013
Case-control study of 239 consecutive SLE patients meeting ACR criteria and 278 age/ethnicity-matched Italian controls; genotyping by allelic discrimination with TaqMan probes. The three TRAF3IP2-panel SNPs (rs33980500, rs13190932, rs13193677) were genotyped together. rs13193677 showed association with SLE susceptibility at P=0.046, OR=1.73, reaching nominal significance. The effect was comparable to rs33980500 (P=0.021, OR=1.71) but with borderline statistical confidence — consistent with a modest additive risk contribution rather than a strong causal effect.

All three SNPs were associated with pericarditis development as a disease complication, with rs33980500 showing the strongest pericarditis association (P=0.002, OR=2.59). The combined pericarditis signal across the panel suggests either shared haplotype effects, shared immune pathways, or that the specific SLE autoimmune cardiac manifestation is particularly sensitive to variation at these loci. Pericarditis occurs in 20–30% of SLE patients over their disease course and is a major driver of morbidity and hospitalisation.

The OR of 1.73 is moderate in magnitude and derives from a single study in an Italian cohort (n=517 total). Independent replication in larger and more diverse SLE cohorts has not been published to date. This limits confidence to the moderate evidence tier: biologically plausible IL-17 pathway connection, nominal statistical significance, but not yet replicated at genome-wide significance in SLE-specific GWAS.

Practical Actions

Carriers of the A allele should be aware of its association with SLE susceptibility and particularly with pericarditis as a disease manifestation. Early recognition of pericarditis symptoms in SLE patients — pleuritic chest pain worsened by lying flat, friction rub on auscultation, pericardial effusion on echocardiography — is critical because SLE pericarditis responds to colchicine and NSAIDs when identified early, and tamponade or constrictive pericarditis can complicate untreated or recurrent episodes.

Given the borderline statistical confidence and single-cohort evidence base, this variant is best interpreted as a modifier that, when co-occurring with other SLE susceptibility alleles or in individuals with established SLE, raises awareness for cardiac monitoring.

Interactions

rs13193677 was studied alongside rs33980500 (D10N) and rs13190932 (R74W) as part of the TRAF3IP2 variant panel in the Ciccacci 2013 cohort. All three variants showed association with pericarditis development, suggesting additive or independent contributions across the panel to cardiac autoimmune risk in SLE.

rs33980500 (D10N) and rs13190932 (R74W) are the primary functional and GWAS variants at the TRAF3IP2 locus. D10N disrupts Act1-TRAF6 binding and paradoxically drives Th17 hyperactivation; R74W is the strongest GWAS signal for psoriatic arthritis. These coding variants operate through the IL-17 pathway in skin and joints; their contribution to SLE pericarditis through the same pathway — IL-17 drives pericardial inflammation — provides a mechanistic frame for the Ciccacci 2013 findings.

rs2476601 (PTPN22 R620W) is an established SLE susceptibility variant. Carrying both rs13193677-A and rs2476601-A would represent convergent risk from the IL-17 signaling and T-cell activation checkpoints respectively.

A single letter change in the SLC24A5 gene — replacing alanine with threonine at position 111 of the protein — is the largest known contributor to lighter skin pigmentation in humans¹¹ the largest known contributor to lighter skin pigmentation in humans
Lamason RL et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science. 2005. This variant alone explains 25-38% of the difference in skin melanin between people of European and West African ancestry, making it one of the most impactful genetic variants for any visible human trait.

SLC24A5 encodes a potassium-dependent sodium-calcium exchanger²² potassium-dependent sodium-calcium exchanger
NCKX5, a member of the solute carrier family that transports ions across cell membranes located on the membrane of melanosomes — the specialized compartments within skin cells where melanin is synthesized and stored. The ancestral alanine variant allows normal calcium exchange and melanin production, while the derived threonine variant reduces calcium-exchange activity, disrupting the pH balance needed for proper melanin synthesis.

The Mechanism

Melanin production requires a carefully orchestrated sequence of enzymatic reactions inside melanosomes. The key enzyme, tyrosinase, must undergo proper maturation in the trans-Golgi network³³ trans-Golgi network
a cellular sorting station that processes and packages proteins before being transported to melanosomes. This maturation process is exquisitely sensitive to pH and calcium levels.

SLC24A5 normally transports calcium out of the trans-Golgi network in exchange for sodium and potassium. When the Ala111Thr variant reduces this calcium-exchange activity, the altered calcium concentration acidifies the trans-Golgi network⁴⁴ the altered calcium concentration acidifies the trans-Golgi network
Quillen EE & Shriver MD. Unpacking human skin pigmentation. Cell. 2011, impairing tyrosinase maturation and decreasing its catalytic efficiency. The result: melanocytes produce substantially less melanin even when all the enzymatic machinery is present and functional.

Studies using zebrafish carrying the equivalent variant demonstrate this clearly — the fish develop a characteristic "golden" phenotype with dramatically reduced melanin, and the same molecular mechanism operates in human skin cells.

The Evidence

The Ala111Thr variant (rs1426654, nucleotide change G→A) is nearly fixed in European populations at 98.7-100% frequency⁵⁵ nearly fixed in European populations at 98.7-100% frequency
Crawford NG et al. Loci associated with skin pigmentation identified in African populations. Science. 2017, while the ancestral alanine form predominates at 93-100% in Sub-Saharan African, East Asian, and Indigenous American populations. This dramatic frequency difference makes rs1426654 one of the most powerful ancestry-informative markers⁶⁶ ancestry-informative markers
genetic variants that differ substantially in frequency across continental populations in the human genome.

South Asian populations show intermediate frequencies⁷⁷ South Asian populations show intermediate frequencies
Mallick CB et al. The light skin allele of SLC24A5 in South Asians and Europeans shares identity by descent. PLoS Genet. 2013 (averaging 53%, ranging from 3% to 100% across the subcontinent), and genetic dating analyses indicate the light-skin allele in Europeans and South Asians shares a common origin through identity by descent, with coalescence estimated at 22,000-28,000 years ago. The variant shows one of the strongest genomic signatures of positive selection in Europeans, consistent with rapid adaptation after ancestral populations migrated to high-latitude environments with reduced UV radiation.

In a quantitative skin pigmentation study of 1,228 South Indians, rs1426654 genotype alone explained 27% of the total variation in melanin index⁸⁸ rs1426654 genotype alone explained 27% of the total variation in melanin index
with a likelihood ratio test showing p = 2.4×10⁻³¹ and odds ratio of 26.2 for the lighter-skin allele. Among Brazilian melanoma patients and controls, the AA genotype conferred a 7-fold increased melanoma risk⁹⁹ the AA genotype conferred a 7-fold increased melanoma risk
Reis LB et al. Skin pigmentation polymorphisms associated with increased risk of melanoma. BMC Cancer. 2020 (OR = 7.13, 95% CI: 1.87-27.11, p < 0.01) compared to GG, consistent with the established relationship between lighter skin and UV-induced DNA damage.

Practical Actions

Your genotype at this variant determines your baseline skin pigmentation capacity, which has direct implications for UV sensitivity, vitamin D synthesis, and skin cancer risk. The genetic mechanism is clear and the effect size is large — this isn't a subtle statistical association but a fundamental determinant of how your skin responds to sunlight.

For AA genotypes (light skin variant): Your reduced melanin production means less natural UV protection. You sunburn more easily, accumulate UV-induced DNA damage more rapidly, and face elevated melanoma and non-melanoma skin cancer risk. However, your skin synthesizes vitamin D more efficiently at low UV levels, which was adaptive for ancestral populations at northern latitudes but creates a tradeoff in modern sun-exposure patterns. Rigorous sun protection is essential — broad-spectrum sunscreen (SPF 30-50), protective clothing, and UV-avoidance during peak hours. Monitor for suspicious skin changes and establish regular dermatological surveillance, especially if you have additional risk factors (fair hair, blue eyes, family history).

At the same time, lighter skin means you need less sun exposure to maintain vitamin D levels¹⁰¹⁰ less sun exposure to maintain vitamin D levels
the Ala111Thr variant enhances vitamin D synthesis efficiency at high latitudes with limited UV. At latitudes above 35°N during winter months (November-March), UVB radiation is insufficient for vitamin D synthesis regardless of skin type¹¹¹¹ UVB radiation is insufficient for vitamin D synthesis regardless of skin type
Webb AR et al. Influence of season and latitude on cutaneous synthesis of vitamin D₃. J Clin Endocrinol Metab. 1988, making supplementation necessary to maintain adequate circulating 25(OH)D levels.

For GG genotypes (dark skin variant): Your higher melanin content provides substantial natural UV protection, reducing sunburn susceptibility and skin cancer risk. However, melanin also absorbs UVB radiation before it can trigger vitamin D synthesis — people with very dark skin may require up to 10 times longer sun exposure¹²¹² up to 10 times longer sun exposure
to produce equivalent vitamin D levels compared to fair-skinned individuals. At high latitudes or during winter, this can make it nearly impossible to maintain adequate vitamin D through sun exposure alone. Year-round vitamin D supplementation (1000-2000 IU daily, or higher if blood tests confirm deficiency) is advisable, particularly if you live far from the equator.

For AG genotypes (intermediate): You have moderate melanin production — better UV protection than AA homozygotes but less than GG, and intermediate vitamin D synthesis efficiency. Standard sun protection practices apply (SPF 30, reapplication every 2 hours, protective measures during peak UV), and vitamin D status should be monitored through blood testing, with supplementation adjusted accordingly.

Interactions

SLC24A5 is part of a broader polygenic architecture controlling human pigmentation. While rs1426654 is the single largest contributor, it interacts with variants in other pigmentation genes to determine your overall skin, hair, and eye color phenotype.

SLC45A2 rs16891982¹³¹³ SLC45A2 rs16891982
another sodium-calcium exchanger variant, p.Leu374Phe is the second-largest contributor to European skin lightening and shows strong epistatic interaction with SLC24A5¹⁴¹⁴ shows strong epistatic interaction with SLC24A5
individuals homozygous for derived alleles at both loci have lighter skin than predicted from additive effects. Similarly, TYR rs1042602¹⁵¹⁵ TYR rs1042602
the gene encoding tyrosinase itself, p.Ser192Tyr and OCA2/HERC2 rs12913832¹⁶¹⁶ OCA2/HERC2 rs12913832
the master regulator of eye color contribute additional variation, and simultaneous genotyping of rs1426654, rs16891982, and rs1042602 has been validated for forensic pigmentation prediction¹⁷¹⁷ simultaneous genotyping of rs1426654, rs16891982, and rs1042602 has been validated for forensic pigmentation prediction
Soejima M et al. Simultaneous genotyping of three SNVs involved in skin pigmentation. Hum Mutat. 2025.

The combined effect of these variants determines not only baseline pigmentation but also your capacity to tan (facultative pigmentation) and how your skin ages under UV exposure. If you carry light-skin variants at multiple loci, the cumulative effect on UV sensitivity and cancer risk is greater than any single variant alone — making comprehensive sun protection even more critical.

From an evolutionary perspective, SLC24A5 illustrates how human populations balanced competing selective pressures¹⁸¹⁸ human populations balanced competing selective pressures
the vitamin D-folate hypothesis during migrations out of Africa. At equatorial latitudes, dark skin protects folate from UV-induced photolysis (critical for DNA synthesis and fetal development), while at high latitudes, lighter skin facilitates vitamin D synthesis under low-UV conditions (essential for calcium homeostasis and immune function). The rapid selective sweep of rs1426654 in Europeans reflects strong positive selection for this physiological tradeoff in novel UV environments.

Your fat cells hold a carefully balanced switch between storing and releasing fat. Phosphodiesterase 3B (PDE3B) is the enzyme that applies the brake. It degrades cAMP¹¹ cAMP
cyclic adenosine monophosphate, a second messenger that activates hormone-sensitive lipase and triggers fat breakdown in adipocytes. When PDE3B functions normally, it limits how strongly stress hormones like adrenaline can stimulate fat burning — a regulatory safeguard that in some contexts becomes a metabolic bottleneck. Carriers of the rare R783X loss-of-function variant have a partially disabled brake, which translates into measurably different lipid profiles and fat distribution patterns compared to the general population.

The Mechanism

The rs150090666 C>T variant introduces a premature stop codon at amino acid position 783, truncating the PDE3B protein within its catalytic domain (p.Arg783Ter). The truncated protein lacks the C-terminal portion needed for full phosphodiesterase activity. With a partially or fully inactive PDE3B, cAMP accumulates more readily in adipocytes in response to catecholamines (epinephrine, norepinephrine) and glucagon, sustaining protein kinase A (PKA) signaling longer than normal. PKA phosphorylates hormone-sensitive lipase (HSL)²² PKA phosphorylates hormone-sensitive lipase (HSL)
HSL is the enzyme that cleaves triglycerides stored in fat droplets into free fatty acids for export, so elevated cAMP drives enhanced lipolysis. The net effect is a shift away from visceral fat storage and toward a more favorable lipid phenotype.

The Evidence

The most detailed human evidence comes from Koprulu et al. (2022, PMID 34875679)³³ Koprulu et al. (2022, PMID 34875679), who examined rare loss-of-function variants across 450,562 UK Biobank participants. The PDE3B p.R783X variant (rs150090666, T allele frequency ~0.1%) was significantly associated with lower waist-to-hip ratio adjusted for BMI (WHRadjBMI; P = 1.41 × 10⁻⁶), with a beta of −0.39 standard deviations in women and −0.10 in men — a sex-biased effect consistent with sex differences in fat distribution genetics more broadly. The variant was also associated with lower triglycerides, higher HDL cholesterol, higher apolipoprotein A1, and a statistically significant reduction in cardiovascular disease risk when meta-analyzed across multiple cohorts.

Tanigawa et al. (2019, PMID 31492854)⁴⁴ Tanigawa et al. (2019, PMID 31492854) independently identified rs150090666 as a protein-truncating variant substantially contributing to obesity-related traits across 2,138 phenotypes in 337,199 UK Biobank participants, and demonstrated PDE3B expression rises sharply during adipogenesis in both mouse (3T3-L1) and human (SGBS) adipocytes — consistent with a primary role in mature fat cell biology. Agrawal et al. (2022, PMID 35773277)⁵⁵ Agrawal et al. (2022, PMID 35773277) replicated the fat distribution association and showed the effect is most prominent in the gluteofemoral depot, a pattern linked to lower cardiometabolic risk. A complementary GWAS in African ancestry populations Ng et al. 2017, PMID 28430825⁶⁶ Ng et al. 2017, PMID 28430825 confirmed PDE3B as a locus for WHRadjBMI, with novel associations in women.

At the cellular level, DiPilato et al. (2015, PMID 26031333)⁷⁷ DiPilato et al. (2015, PMID 26031333) showed that adipocytes genetically lacking PDE3B cannot suppress lipolysis in response to insulin, confirming PDE3B's central role in cAMP-mediated fat regulation. Mowers et al. (2013, PMID 24368730)⁸⁸ Mowers et al. (2013, PMID 24368730) demonstrated that chronic inflammation in obesity hyper-activates PDE3B through IKKε and TBK1 kinases, blunting cAMP signaling and causing catecholamine resistance — precisely the pathway that loss of PDE3B function circumvents.

Practical Actions

Carriers of the T allele (CT heterozygotes) carry one partially inactivated PDE3B copy. The phenotypic signal — higher HDL, lower triglycerides, favorable fat distribution — is real and measurable in large population studies. The effect size for a single copy is modest (lipid differences of a few mg/dL; WHRadjBMI beta of approximately −0.10 in pooled analyses), but the direction is consistently favorable for cardiovascular risk. Carriers should confirm these benefits are reflected in their actual lipid panel. If triglycerides or HDL are unexpectedly outside the favorable range despite this genotype, other variants (LPL, APOE, FADS1/2, ANGPTL3) or lifestyle factors may be dominant.

Interactions

PDE3B sits at the intersection of insulin signaling and adrenergic lipolysis. Its loss-of-function phenotype is most pronounced when catecholamine tone is high (fasting, aerobic exercise, cold exposure) — conditions that would normally activate lipolysis but are partially blunted by PDE3B in wild-type individuals. Variants in ADRB3 (rs4994), which encodes the beta-3 adrenergic receptor, may amplify or attenuate the lipolytic response in PDE3B loss-of-function carriers. Variants affecting lipid clearance (APOE rs429358, LPL rs328) operate downstream of lipolysis on free fatty acid and triglyceride disposal — their combined effect with PDE3B LoF is uncharacterized but potentially additive for triglyceride lowering.

Running just 80 kilobases downstream of the widely-studied rs2681472 variant at the same gene, rs17249754 is an independent intronic variant in ATP2B1¹¹ ATP2B1
encodes Plasma Membrane Ca²⁺-ATPase 1 (PMCA1), the primary pump ejecting calcium from inside cells to the extracellular space — essential for maintaining low intracellular calcium in vascular smooth muscle. Like its neighboring variant, rs17249754 has reached genome-wide significance in multiple large international consortia, but its risk story has an unusual twist: the common G allele (~83% in Europeans, ~65% in East Asians) is the blood pressure-raising allele, while the rarer A allele is protective. Most people carry at least one G allele without knowing it.

The Mechanism

rs17249754 sits within an intron of ATP2B1 on chromosome 12q21.33, position 89,666,809 (GRCh38)²² chromosome 12q21.33, position 89,666,809 (GRCh38). The intronic location means it does not alter the protein sequence of PMCA1 directly; instead, it acts as a regulatory variant affecting gene expression levels in vascular tissue. The G allele is associated with reduced ATP2B1 expression in arterial and aortic endothelial cells — fewer functional PMCA1 pumps per cell.

PMCA1 is the dominant calcium extrusion mechanism in vascular smooth muscle cells. When pump density falls, intracellular calcium rises, driving sustained smooth muscle contraction and vasoconstriction. Separately, PMCA1 physically associates with eNOS³³ eNOS
endothelial nitric oxide synthase, which produces the vasodilator nitric oxide: impaired PMCA1 activity reduces eNOS output, removing a key vasodilatory signal. Both effects — higher calcium and lower nitric oxide — converge on elevated vascular resistance and raised blood pressure.

Mouse models directly validate this pathway: heterozygous PMCA1-null animals develop elevated blood pressure, and vascular smooth muscle-specific knockout mice show increased intracellular calcium with hypertension. Strikingly, aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises⁴⁴ aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises, suggesting subclinical vascular remodelling may precede measurable hypertension by years.

The Evidence

The ICBP consortium analysis⁵⁵ ICBP consortium analysis
International Consortium for Blood Pressure Genome-Wide Association Studies in approximately 200,000 European-ancestry participants placed rs17249754 among 29 genome-wide significant blood pressure loci: each G allele raises systolic BP by 0.928 mmHg (p=1.8×10⁻¹⁸) and diastolic BP by 0.522 mmHg (p=1.2×10⁻¹⁴). These effect sizes are per-allele, meaning GG homozygotes carry approximately 1.86 mmHg higher systolic and 1.04 mmHg higher diastolic BP than the rare AA genotype.

The original Korean discovery⁶⁶ original Korean discovery in 16,703 Korean participants (KARE and Health2 cohorts) found rs17249754 was the strongest ATP2B1 signal for hypertension (p=4.25×10⁻⁹) — stronger than the neighboring rs2681472, which predominates in European analyses. A 2021 meta-analysis of 65,362 individuals across 9 studies⁷⁷ 2021 meta-analysis of 65,362 individuals across 9 studies confirmed the association globally: hypertension OR=1.19 (95%CI 1.10–1.28) per G allele. Cross-ethnic replication in 55,383 East Asian participants (stage 1+2)⁸⁸ in 55,383 East Asian participants (stage 1+2) confirmed the locus for mean arterial pressure (p=7.5×10⁻¹⁵) and pulse pressure (p=1.2×10⁻⁵). Replication extends to African (Burkina Faso), Chinese children, and South Asian populations.

A critical dietary interaction has been documented. In a Korean cohort of 14,354 participants⁹⁹ Korean cohort of 14,354 participants, G allele (major allele) carriers showed substantially higher systolic BP risk when calcium intake was low and the dietary sodium-to-potassium ratio was high. Conversely, A allele carriers (the protective minority) gained the greatest benefit from high potassium intake and a low sodium-to-potassium ratio. This gene-diet interaction is directly actionable: PMCA1 insufficiency from the G allele is exacerbated when dietary calcium is unavailable to compensate for impaired efflux.

Practical Actions

For GG carriers, three strategies target the underlying mechanism most directly. Maintaining dietary calcium at 1,000–1,200 mg/day is the most genotype-specific intervention: low calcium amplifies the blood pressure risk from reduced PMCA1 activity at a cellular level. Reducing the dietary sodium-to-potassium ratio — through sodium reduction and potassium-rich foods — addresses the salt-sensitivity component documented in this variant's cohort studies. Regular home blood pressure monitoring enables early detection of the gradual pressure elevation this variant drives. For AG heterozygotes, the same dietary targets apply with attenuated urgency — the additive effect model means they carry approximately half the genotype-attributable BP elevation.

Interactions

rs17249754 and rs2681472 are both intronic ATP2B1 variants in partial linkage disequilibrium. rs2681472 is the stronger signal in European-ancestry GWAS; rs17249754 is stronger in East Asian cohorts. Carriers of risk alleles at both variants may have compounded calcium-mediated BP elevation, though formal compound action studies documenting the interaction effect are not yet published.

Within the blood pressure regulatory network, ATP2B1 interacts functionally with AGT (rs699, angiotensinogen M235T) and NOS3 (rs1799983, eNOS Glu298Asp). Angiotensin II elevates intracellular calcium in vascular smooth muscle — a signal that depends on PMCA1 for clearance. Reduced PMCA1 in G allele carriers means angiotensin II-driven calcium signals persist longer. Similarly, impaired PMCA1 reduces the calcium/calmodulin signal available to activate eNOS, compounding the effect of any eNOS Glu298Asp-associated nitric oxide deficit.

BANK1 (B-cell scaffold protein with ankyrin repeats 1) is expressed almost exclusively in B cells, where it orchestrates two interconnected arms of immune signaling: B-cell receptor (BCR) activation¹¹ B-cell receptor (BCR) activation
BANK1 scaffolds LYN kinase, IP3 receptors, and PLCγ2 into a complex that mobilizes calcium from the endoplasmic reticulum upon antigen engagement and toll-like receptor (TLR) signaling²² toll-like receptor (TLR) signaling
BANK1 full-length isoform contains a TIR domain in exon 2 that directly binds the TLR adaptor MyD88, linking BANK1 to innate immune pattern-recognition signaling in B cells. The rs17266594 variant sits in intron 1 of BANK1 at the branch-point sequence — a short RNA motif that the spliceosome uses to determine whether exon 2 is included in the mature mRNA. This single intronic change controls which of two BANK1 proteins a B cell predominantly produces, with downstream consequences for both BCR and TLR arms of B-cell activation.

The Mechanism

Alternative splicing of BANK1 produces two isoforms: the full-length (FL) protein that retains exon 2, and the Delta2 (Δ2) isoform that skips exon 2 entirely. Exon 2 encodes a Toll/IL-1 receptor (TIR) domain³³ Toll/IL-1 receptor (TIR) domain
The TIR domain is a conserved protein interaction module found in toll-like receptors and their adaptors; it mediates signal propagation through homotypic TIR-TIR interactions — the same class of domain that enables MyD88 to propagate signals from TLR7 and TLR9 after recognition of viral RNA and DNA.

The rs17266594 variant alters the branch-point consensus sequence immediately upstream of exon 2. The T allele (risk) shifts the isoform balance toward full-length BANK1⁴⁴ T allele (risk) shifts the isoform balance toward full-length BANK1
T allele correlates with higher FL:Δ2 ratio; C allele correlates with higher Δ2 expression in homozygous protective carriers, meaning T carriers produce proportionally more TIR-domain-containing BANK1. The C allele (protective) promotes exon 2 skipping, favoring the Δ2 isoform that lacks the TIR domain.

The functional consequence is mechanistically clear: BANK1-Δ2, lacking the TIR domain, shows significantly reduced binding to MyD88⁵⁵ BANK1-Δ2, lacking the TIR domain, shows significantly reduced binding to MyD88
Co-immunoprecipitation experiments demonstrated markedly decreased BANK1-Δ2 interaction with MyD88 compared to BANK1-FL, confirming the TIR domain is essential for this interaction compared to full-length BANK1. This matters because TLR7 and TLR9 in B cells drive interferon-alpha production and autoantibody generation — the molecular signature of active SLE. When BANK1-FL dominates (T allele), B cells have a stronger TLR-MyD88 signaling axis, amplifying innate immune responses that can break self-tolerance. When BANK1-Δ2 dominates (C allele), this TLR arm is dampened.

rs17266594 is in strong linkage disequilibrium with rs10516487 (R61H) — r²=0.9 in Europeans and r²=1 in Chinese populations — meaning they are nearly always coinherited. The SLE risk haplotype is TGG across rs17266594-rs10516487-rs3733197, while the protective haplotype is CAA. Despite near-complete LD, the two SNPs affect distinct molecular processes: rs10516487 modifies scaffolding complex multimerization and SRp40 splicing enhancer activity, while rs17266594 affects branch-point recognition. Together they constitute a coordinated isoform-control mechanism.

The Evidence

The variant was co-discovered with rs10516487 and rs3733197 in the original BANK1 genome-wide association study⁶⁶ original BANK1 genome-wide association study
Kozyrev et al. used 85,042 SNPs across European SLE cases and controls, identifying rs17266594 as a branch-point splice variant with differential isoform expression dependent on this SNP. In a dedicated European-ancestry replication study of 1,892 SLE cases and 2,652 controls, rs17266594 showed the strongest association signal⁷⁷ rs17266594 showed the strongest association signal
Despite being intronic, rs17266594 produced the strongest BANK1-SLE signal in this cohort: corrected P=1.97×10⁻⁵, OR=1.22 (95% CI 1.12–1.34) among all BANK1 variants tested — a notable finding for a non-coding SNP.

Replication across ancestries is robust. In Hong Kong Chinese⁸⁸ Hong Kong Chinese
949 SLE cases, 1,042 controls; the protective C allele OR=0.61 (95% CI 0.51–0.72), P=4.67×10⁻⁹, with r²=1 LD with rs10516487 in HapMap HCB Chinese, the association was stronger than in Europeans. In Chinese Han patients, the T allele was enriched among SLE patients and was significantly associated with high-titre ANA and anti-SSA antibodies⁹⁹ significantly associated with high-titre ANA and anti-SSA antibodies
Among BANK1 variant carriers with SLE, rs17266594 T allele showed specific enrichment for ANA ≥1:320 and Ro/SSA autoantibodies — autoantibody specificities that mark active, organ-threatening disease.

A meta-analysis of 22 studies¹⁰¹⁰ meta-analysis of 22 studies
Bae and Lee 2017; 22,684 patients and 36,437 controls across SLE, RA, and SSc; BANK1 rs17266594 T allele pooled OR=1.19 (95% CI 1.07–1.32), P=0.001 across all autoimmune diseases confirmed the disease-specific pattern: significant association for SLE (OR=1.41) and systemic sclerosis (OR=1.09), but no significant RA association — distinguishing rs17266594 from rs3733197 (A383T), which does associate with RA when the BLK risk background is also present.

B-cell functional studies showed that individuals carrying the BANK1 risk haplotype (TGG) have altered proximal BCR signaling¹¹¹¹ altered proximal BCR signaling
Risk haplotype carriers show reduced phospho-PLCγ2 and phospho-AKT, increased FOXO1 expression, and expanded memory B-cell compartment — a pro-autoimmune B-cell developmental bias, with expanded memory B cells and blunted immediate BCR activation markers, consistent with a B-cell population primed for autoantibody differentiation over acute antigen response.

Practical Actions

Carrying the TT genotype means your BANK1 produces predominantly the full-length isoform with intact TIR domain, giving your B cells enhanced responsiveness to both BCR stimulation and TLR7/TLR9 ligands such as viral RNA and DNA. This does not cause autoimmune disease independently — environmental triggers (UV light, viral infections, estrogen cycling), HLA haplotype, and other BANK1 and BLK variants are all required co-factors. Most T allele carriers will never develop SLE or SSc. However, the variant meaningfully shifts probability, and early recognition of symptoms — malar rash, persistent joint pain, Raynaud's phenomenon, persistent dry mouth or eyes, photosensitivity — warrants prompt rheumatologic evaluation rather than watchful waiting.

Because rs17266594 and rs10516487 are in near-complete LD, their clinical implications substantially overlap: both tag the same risk haplotype in most individuals. Where they differ is in Chinese populations (r²=1) where rs17266594 is the sole independent tag needed, and in the specific mechanism it illuminates — the TLR-MyD88 axis — which has direct therapeutic relevance. Belimumab (anti-BAFF) and hydroxychloroquine remain the best-evidenced interventions for SLE once diagnosed, regardless of BANK1 genotype. However, the TLR-MyD88 connection suggests that TLR7/TLR9 antagonists (under clinical development for SLE) may be particularly relevant for T allele carriers.

Interactions

rs17266594 is nearly always coinherited with rs10516487 (R61H) as part of the BANK1 risk haplotype TGG (rs17266594-rs10516487-rs3733197). The two SNPs affect distinct molecular mechanisms — branch-point splicing versus SRp40 splicing enhancer and protein multimerization — but their effects converge on the same phenotype (increased full-length:Δ2 isoform ratio and amplified B-cell activation). When interpreting these two SNPs, genotype concordance is expected in most people; a rare discordant individual (TC at rs17266594, GG at rs10516487) may have partially additive effects.

The BLK rs13277113 variant (reduced BLK expression in B cells) shows documented gene-gene interaction with BANK1 variants¹²¹² documented gene-gene interaction with BANK1 variants
BLK and BANK1 gene-gene interaction confirmed by logistic regression (P=0.013), MDR (P<0.0001), and linear regression (P=0.0017) in SLE susceptibility — when risk alleles at both loci are present, the combined SLE risk substantially exceeds individual contributions. Similarly, STAT4 rs7574865 (amplified JAK-STAT interferon signaling) compounds with BANK1 variants because the TLR-MyD88-IFN-α axis activated by full-length BANK1 feeds directly into the STAT4 pathway. Individuals carrying risk alleles at rs17266594 (or rs10516487), rs13277113, and rs7574865 simultaneously represent the highest-risk genetic tier for SLE among the SNPs in this database.

STAT3¹¹ STAT3
Signal Transducer and Activator of Transcription 3 — a transcription factor that acts as a central relay converting cytokine signals into gene expression changes sits at the convergence point of nearly every inflammatory circuit driving atopic dermatitis. When cytokines dock on their receptors at the skin cell surface, receptor-associated JAK kinases²² JAK kinases
Janus kinase family: JAK1, JAK2, JAK3, TYK2 — the enzymes that phosphorylate and activate STAT proteins phosphorylate STAT3, which then dimerizes and travels to the nucleus to switch on inflammation-promoting genes. This intronic variant in STAT3 emerged as one of 91 loci in the largest atopic dermatitis genome-wide association study ever conducted, with replication across nearly three million individuals.

The Mechanism

rs17881320 lies within an intron of STAT3 (chromosome 17q21.2, GRCh38 position 42,333,221). As an intronic variant rather than a coding change, it does not alter the STAT3 protein sequence directly. Instead, it is a regulatory tag: the T allele likely disrupts an intronic regulatory element — an enhancer or splicing regulatory sequence³³ enhancer or splicing regulatory sequence
DNA sequences within introns that influence how much protein is made or which transcript isoforms are produced — that alters STAT3 expression level or isoform ratio in immune and skin cells. The exact functional mechanism at the molecular level has not yet been characterized for this specific SNP; its disease relevance is established by population genetics rather than experimental protein studies.

In the context of atopic dermatitis, STAT3 functions as the primary downstream effector of several key inflammatory cytokines: IL-22 signals almost exclusively through STAT3 to suppress skin barrier gene expression; IL-31 activates STAT3 to drive the neurogenic itch–inflammation cycle; and TSLP, IL-4, and IL-13 all activate STAT3 as a secondary pathway alongside the better-known STAT6 route. Altered STAT3 output — whether higher baseline expression, changed isoform balance, or altered inducibility — would amplify the cytokine cascade already central to AD.

The Evidence

The association was established by Budu-Aggrey et al.⁴⁴ Budu-Aggrey et al.
"European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation," Nature Communications 2023, the largest AD GWAS to date. Discovery phase: 862,032 individuals across 38 studies; the T allele reached OR=1.09 (95% CI 1.07–1.12, p=5.34×10⁻¹³). Replication was conducted in an independent 23andMe European cohort of 2,904,664 individuals, where the T allele confirmed OR=1.07 (p=9.8×10⁻³⁹). The variant is annotated to the "Cytokine signalling in immune system" pathway. The study identified 91 total AD loci, with the STAT3 hit among 29 newly discovered European loci — underscoring that STAT3 pathway dysregulation is a primary driver of AD susceptibility, not merely incidental.

The OR of 1.09 per T allele is typical for common GWAS variants in complex traits: individually modest, but mechanistically informative. Homozygous TT carriers (rare, ~0.4% of Europeans) carry approximately 1.09² ≈ 1.19-fold elevated AD risk compared to GG, while GT heterozygotes (~17% of Europeans) carry ~1.09-fold elevated risk. The variant's significance lies in what it points to — the JAK-STAT3 axis — rather than in its magnitude as a standalone risk factor.

The direct clinical relevance comes from the drug pipeline the same pathway generated. Three oral JAK inhibitors are now FDA-approved for moderate-to-severe AD: upadacitinib (Rinvoq)⁵⁵ upadacitinib (Rinvoq)
JAK1-selective inhibitor; approved 2022 for moderate-to-severe AD, baricitinib (Olumiant)⁶⁶ baricitinib (Olumiant)
JAK1/2 inhibitor; approved 2022 for moderate-to-severe AD, and abrocitinib (Cibinqo, JAK1-selective). All three suppress STAT3 phosphorylation downstream of the cytokines driving AD. Topical ruxolitinib (Opzelura, JAK1/2) is also approved for mild-to-moderate disease.

Practical Actions

Knowing you carry the T allele does not change first-line AD management, but it does clarify the biological pathway driving your disease. For patients with moderate-to-severe AD who do not respond adequately to topical corticosteroids or dupilumab, the JAK-STAT3 pathway is a validated therapeutic target. JAK inhibitors block the very pathway this variant tags. If your dermatologist is considering systemic therapy, sharing this genetic context with them is worthwhile — it supports selecting JAK inhibitors as a mechanistically matched option.

Environmental and dietary factors that drive JAK-STAT3 signaling in skin include excessive IL-6 production (amplified by visceral adiposity and gut dysbiosis), chronic scratching-induced TSLP release, and deficient long-chain omega-3 fatty acids, which shift skin immune cell membranes toward a pro-inflammatory arachidonic acid profile.

Interactions

STAT3 variants do not act in isolation within the JAK-STAT pathway. Other signaling components, including rs2293152⁷⁷ rs2293152
STAT3 3'UTR variant, also associated with AD and Crohn's disease in multiple GWAS, rs744166⁸⁸ rs744166
STAT3 intronic variant associated with inflammatory bowel disease and autoimmune phenotypes, and variants in upstream JAK kinase genes, collectively define an individual's JAK-STAT signaling tone. Compound effects across the pathway have not been formally modeled for this specific locus, but STAT3 pathway variant burden is an active research area in AD pharmacogenomics.

Coagulation Factor V is a large plasma protein with a dual role in hemostasis: it accelerates clot formation by amplifying thrombin generation, and it also assists activated protein C (APC) in switching off this cascade. The rs1800595 variant — known as the R2 polymorphism, H1299R, or the HR2 haplotype — subtly shifts that balance toward clotting, but only mildly when inherited alone. Its chief clinical importance emerges when it co-occurs with Factor V Leiden (rs6025) on the opposite chromosome, a combination that amplifies thrombotic risk far beyond what either variant produces independently.

The Mechanism

The F5 gene sits on chromosome 1's minus strand. The rs1800595 C allele (plus-strand) corresponds to a guanine substitution (A4070G) in the coding sequence, replacing histidine with arginine at position 1327 of the mature protein¹¹ position 1327 of the mature protein
Modern NM_000130.5 numbering; older literature used His1299Arg based on an earlier reference transcript; both terms refer to the same variant. This substitution lies in the B domain of Factor V — a large central domain that is cleaved off during activation but influences the protein's interactions with other coagulation factors.

The molecular consequence, described by Castoldi and colleagues in 2004²² described by Castoldi and colleagues in 2004
Castoldi E et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004;103:4173-9, is a partial loss of Factor V's anticoagulant cofactor activity: FV(R2) retains only 73% of normal Factor V's ability to assist APC in inactivating Factor VIIIa. This contrasts sharply with Factor V Leiden, which simultaneously resists APC-mediated inactivation of itself AND loses its APC cofactor function entirely. The R2 mechanism is subtler: the protein is still inactivated normally by APC, it simply cooperates less efficiently with APC to shut down the coagulation cascade. Carriers also produce modestly reduced Factor V plasma levels³³ modestly reduced Factor V plasma levels
An increasing frequency of the Arg1299 allele correlates with decreasing mean plasma Factor V activity; homozygotes are not clinically symptomatic.

The Evidence

HR2 alone: Population studies consistently show a borderline or non-significant association between HR2 and venous thromboembolism (VTE) risk in isolation. The largest summary of evidence — a 2003 meta-analysis by Castaman et al. covering 2,696 VTE cases and 7,710 controls⁴⁴ a 2003 meta-analysis by Castaman et al. covering 2,696 VTE cases and 7,710 controls
Castaman G et al. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003 — found a pooled OR of 1.15 (95% CI 0.98-1.36), just crossing statistical significance. One smaller but well-designed study found HR2 was 2.7 times more prevalent in VTE patients who lacked Factor V Leiden⁵⁵ 2.7 times more prevalent in VTE patients who lacked Factor V Leiden
Otrock ZK et al. Factor V HR2 haplotype: a risk factor for VTE in individuals with absence of Factor V Leiden. Ann Hematol 2008 compared to FVL-negative controls (OR 2.7, 95% CI 1.04-7.06), suggesting a detectable independent effect in this subgroup.

HR2 + Factor V Leiden compound heterozygosity: This is where the clinical evidence is clearest. In a family-based prospective cohort reported by Meinardi et al. in Blood 1999⁶⁶ Meinardi et al. in Blood 1999
Meinardi JR et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of VTE to carriers of factor V R506Q (FV Leiden). Blood 1999;94:3062-6, patients doubly heterozygous for FV Leiden and HR2 had a hazard ratio of 14.0 (95% CI 3.7-53.4) compared to non-carriers — versus 4.2 for FV Leiden alone. The first VTE event occurred an average of 6 years earlier in double heterozygotes than in carriers of FV Leiden alone. This 3- to 4-fold amplification relative to FV Leiden is biologically explained: in compound heterozygous individuals, the FV Leiden chromosome produces a Factor V that resists APC inactivation, while the HR2 chromosome produces a Factor V that provides inferior APC cofactor support — so both copies of Factor V are impaired in anticoagulant function simultaneously.

For recurrent pregnancy loss, the evidence does not support an independent role for HR2. A 2022 meta-analysis of 13 studies⁷⁷ 2022 meta-analysis of 13 studies
Capra AP et al. Systematic review of FV H1299R and recurrent pregnancy loss. Biology 2022;11:1608 found no significant association (OR 1.18, 95% CI 0.78-1.80).

Practical Implications

For the typical HR2 heterozygous carrier without Factor V Leiden, the absolute risk elevation is modest — similar in magnitude to mild thrombophilic polymorphisms like the MTHFR C677T variant. Routine anticoagulation is not indicated; the variant becomes most relevant in the context of acquired provocation (surgery, immobility, pregnancy, hormonal treatments) or when standard thrombophilia workup yields otherwise unexplained VTE in a patient without FV Leiden.

The critical clinical scenario is the patient whose thrombophilia panel shows FV Leiden and who also carries the HR2 C allele. This compound configuration substantially increases lifetime VTE risk and should prompt more proactive management of thrombotic triggers.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁸⁸ Factor V Leiden (rs6025, F5 R506Q)
The most common inherited thrombophilia in Europeans, present in ~5% of the population; causes complete APC resistance via a different mechanism than HR2. Compound heterozygosity for FV Leiden and HR2 on opposite chromosomes creates a state where neither copy of Factor V functions normally in its anticoagulant role — a multiplicative impairment that approximates the phenotype of FV Leiden homozygosity.

The prothrombin G20210A variant (rs1799963, F2)⁹⁹ prothrombin G20210A variant (rs1799963, F2)
Increases plasma prothrombin 30%, increasing clot-forming capacity; compound risk with any thrombophilic Factor V variant is additive also compounds with the HR2 haplotype, as it increases the procoagulant drive independent of the APC pathway. Any carrier of HR2 should have FV Leiden and prothrombin G20210A status established if a thrombotic event occurs or before high-risk situations.